ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,179,031 | -74.5% | 222,040 | -54.3% | 0.00% | – |
Q2 2023 | $4,631,368 | +24.7% | 485,978 | +43.9% | 0.00% | – |
Q1 2023 | $3,714,194 | +26.7% | 337,654 | +70.5% | 0.00% | – |
Q4 2022 | $2,931,347 | +22.8% | 198,064 | +58.5% | 0.00% | – |
Q3 2022 | $2,387,000 | +3.6% | 124,926 | +15.5% | 0.00% | – |
Q2 2022 | $2,304,000 | +22.7% | 108,169 | +11.0% | 0.00% | – |
Q1 2022 | $1,878,000 | +70.9% | 97,452 | +83.8% | 0.00% | – |
Q4 2021 | $1,099,000 | -68.0% | 53,019 | -63.1% | 0.00% | – |
Q3 2021 | $3,434,000 | -44.5% | 143,746 | -36.6% | 0.00% | -100.0% |
Q2 2021 | $6,185,000 | +70.1% | 226,673 | +80.3% | 0.00% | 0.0% |
Q1 2021 | $3,636,000 | -15.0% | 125,712 | -17.3% | 0.00% | 0.0% |
Q4 2020 | $4,277,000 | +5053.0% | 152,010 | +5323.1% | 0.00% | – |
Q3 2020 | $83,000 | -23.1% | 2,803 | -21.6% | 0.00% | – |
Q2 2020 | $108,000 | +151.2% | 3,573 | +148.6% | 0.00% | – |
Q1 2020 | $43,000 | – | 1,437 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |